Correlation of low CT attenuation and necrotic features of tumor in contrast-enhanced CT with nivolumab response
| العنوان: | Correlation of low CT attenuation and necrotic features of tumor in contrast-enhanced CT with nivolumab response |
|---|---|
| المؤلفون: | Satoru Kitazono, Shingo Nishikawa, Katsunori Oikado, Atsushi Horiike, Makoto Nishio, Tomoaki Sonoda, Junji Koyama, Natsuki Takano, Tomoyo Oguri, Ryo Ariyasu, Yosuke Kawashima, Masafumi Saiki, Noriko Yanagitani, Fumiyoshi Ohyanagi |
| المصدر: | Journal of Clinical Oncology. 35:e23105-e23105 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Cancer Research, biology, Enhanced ct, business.industry, media_common.quotation_subject, Ct attenuation, Correlation, Oncology, biology.protein, Contrast (vision), Medicine, Non small cell, Antibody, Nivolumab, Nuclear medicine, business, media_common |
| الوصف: | e23105 Background: Anti-PD1/PD-L1 antibodies, including nivolumab, produce durable responses in non-small cell lung cancer (NSCLC), but the response rate is about 20% in unselected NSCLC. Identifying predictive markers of response is necessary. Although PD-L1 expression may be a potential biomarker, evaluating whole tumors based on a small sample is difficult. Identifying radiographic features of responders can be very useful. We hypothesized that low attenuation on computed tomography (CT), considered to represent necrosis, correlates with nivolumab response. Methods: We retrospectively evaluated contrast-enhanced CT images before treatment and tumor response in 60 patients receiving nivolumab. The largest tumor lesion was characterized in each patient. CT attenuation (CTA) of whole tumor areas was measured; the presence of radiological findings of necrosis (necrotic features), presenting cavitation or ring- or patchy-enhancement in tumors, were assessed. We evaluated the association between CT imaging characteristics and nivolumab response and that between CT imaging characteristics and PD-L1 expression in tumors. Results: Thirty-nine target lesions in lung, 12 in lymph node, and 9 in other organs were chosen. The mean CTA was 58.5 ± 15.3 HU. Necrotic feature were observed in 24 (40%) of 60 lesions.Twenty of 60 lesions (33%) shrank to > 30% with nivolumab treatment. Mean CTA in responding lesions was 48.6 HU, significantly lower than that in nonresponding lesions (63.4 HU) (p < 0.001). The response rate of lesions with/without necrotic features was 45% and 28%, respectively (p = 0.246).Systemic tumor response, assessed by RECIST v1.1, was confirmed in 20 (33%) patients. Mean CTA of target lesions was lower in responders than patients with stable disease or progressive disease (51.4 vs. 62.0 HU, p = 0.011). The systemic response rate of lesions with/without necrotic features was 50% and 25%, respectively (p = 0.081).Mean CTA of target lesions was lower in tumors with high PD-L1 expression than in tumors with low PD-L1 expression (54.8 vs. 64.4 HU, p = 0.045). Conclusions: Low CTA and necrotic features in CT may correlate with nivolumab response. Tumors with low CTA may have high PD-L1 expression. |
| تدمد: | 1527-7755 0732-183X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::d83e31178dbaa77d6b2422f30656bb1eTest https://doi.org/10.1200/jco.2017.35.15_suppl.e23105Test |
| رقم الانضمام: | edsair.doi...........d83e31178dbaa77d6b2422f30656bb1e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|